SRRKScholar Rock Holding Corporation

1. Sep 14, 2026On September 11, 2026, the Company announced that the FDA has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of SMA in adults and children 2 years of age and older who are currently receiving a survival SMN2 targeted treatment.Regulation FD disclosure · Form 8-K
2. Aug 6, 2026Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
3. Aug 6, 2026As previously disclosed, Scholar Rock Holding Corporation (the “Company”) entered into an Open Market Sale Agreement SM, dated November 14, 2022, with Jefferies LLC (“Jefferies”) relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares …Other event · Form 8-K
4. May 7, 2026Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
5. Mar 31, 2026On March 31, 2026, the Company announced that it resubmitted its BLA to the FDA for apitegromab for the treatment of children and adults with SMA. The Company anticipates FDA acceptance within 30 days and a review period of up to six months from the date of resubmission, with a Prescription Drug User Fee Act (“PDUFA”) …Regulation FD disclosure · Form 8-K
6. Mar 3, 2026Scholar Rock Reports Fourth Quarter and Full.Earnings release · press release
7. Mar 3, 2026Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights.Earnings release · press release
8. Jan 12, 2026The Company will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference (the “Conference”) during the week of January 12, 2026.Earnings release · Form 8-K
9. Dec 2, 2025As previously disclosed, on October 10, 2025, Catalent Indiana, LLC (part of Novo Nordisk) (“Catalent Indiana”) informed Scholar Rock Holding Corporation (the “Company”) that, following the Form FDA 483 issued to Catalent Indiana, LLC on July 14, 2025, the U.S. Food and Drug Administration (the “FDA”) determined that …Other event · Form 8-K
10. Nov 14, 2025As previously disclosed, Scholar Rock Holding Corporation (the “Company”) entered into an Open Market Sale Agreement SM, dated November 14, 2022 with Jefferies LLC (“Jefferies”) relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.